On April 8, Beijing time, the research on engineered dendritic cells and immune tolerance in cardiac remodeling after heart failure was published in Nature.
From zero to one — published in Nature!
Landmark findings from Prof. Xinyang Hu and Prof. Yang Xu’s team at the Second Affiliated Hospital, Zhejiang University School of Medicine: heart failure therapy enters a new era of immune-targeted treatment.